Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-4830 + MK-0482
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MK-4830 + MK-0482 is a combination of two investigational monoclonal antibodies, MK-4830 and MK-0482, being evaluated primarily for the treatment of advanced solid tumors, especially non-small cell lung cancer (NSCLC). MK-4830 targets immunoglobulin-like transcript 4 (ILT4) and acts as a checkpoint inhibitor to promote anti-tumor immunity. MK-0482 targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4, also referred to as ILT3), which is implicated in immunosuppression within the tumor microenvironment. Both antibodies are designed to improve the efficacy of immunotherapies by modulating distinct myeloid cell checkpoint pathways. Developed by Merck Sharp & Dohme (a subsidiary of Merck & Co), this combination is being studied for synergy, often combined with pembrolizumab, another checkpoint inhibitor targeting PD-1. Current research is focused on advanced solid tumors, especially NSCLC and triple-negative breast cancer[3][6][7][8].
- Brand names
- MK-4830 + MK-0482
- Other names
- MK 4830 + MK 0482
02
Targets
LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)LILRB4
Beyond the preview
Go deeper on MK-4830 + MK-0482.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-4830 + MK-0482.